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Purpose: To investigate whether plasma rich in growth factors (PRGF) eye drops
maintain their biological potential after a freeze dryingprocess. The addition of a lyopro-
tectant like trehalose was also evaluated.
Methods: Blood from three healthy donors was collected to obtain eye drops by PRGF
technology. The resultant eye drops were divided in four groups: PRGF, freeze-dried
PRGF (PRGF lyo), and PRGF lyophilized mixed with 2,5% trehalose (PRGF lyo+2.5T) or
5% trehalose (PRGF lyof+5T). Chemical and biological characteristics were evaluated.
Photorefractive keratectomy was performed on C57BL/6 mice which were divided in
three treatment groups: control, PRGF, and PRGF lyo. Corneal wound healing and haze
formationwere evaluatedmacroscopically. Eyeswere collected at 1, 2, 3, and 7days after
surgery, and were processed for histologic studies.
Results: The pH values of PRGF samples increased significantly after the lyophilization
process. Osmolarity levels increased significantly in PRGF samples mixed with trehalose
in comparison with PRGF samples without protectants. The freeze drying process
maintained growth factors levels as well as the biological properties of PRGF eye drops
even without the use of lyoprotectants. PRGF lyo treatment significantly decreased
the re-epithelialization time and haze formation in photorefractive keratectomy-treated
corneas regarding PRGF and control groups. Furthermore, the PRGF lyo group signifi-
cantly decreased the number of smooth muscle actin-positive cells in comparison with
the control group at each time of the study and at days 2 and 3 in the PRGF group.
Conclusions: The freezedryingprocess preserves theprotein andgrowth factor content
as well as the biological properties of PRGF eye drops, even without the use of protec-
tants. Freeze-dried PRGF eye drops accelerate corneal tissue regeneration after photore-
fractive keratectomy in comparison with the control group.
Translational Relevance: Our study shows the feasibility to preserve the biological
capability of PRGF eye drops as freeze-dried formulation, avoiding the addition of
protectants.
Resumen (Foreign Language Abstract):
Objetivo: Investigar si el colirio de plasma rico en factores de crecimiento (PRGF)
mantiene su potencial biológico después de un proceso de liofilización. También se
evaluó la adición de un lioprotector como la trehalosa.
Métodos: Se recogió sangre de tres donantes sanos para obtener colirio mediante la
tecnología PRGF. El colirio resultante se dividió en cuatro grupos: PRGF, PRGF liofil-
izado (PRGF lyo) y PRGF liofilizado mezclado con trehalosa al 2,5% (PRGF lyo + 2.5T)
o trehalosa al 5% (PRGF lyof+ 5T). Se evaluaron las características químicas y biológicas
de cada unode los colirios. Se realizó una queratectomía fotorrefractiva (PRK) en ratones
C57BL/6 que se dividieron en tres grupos de tratamiento: Control, PRGF y PRGF lyo. La
curación de la herida corneal y la formación de “haze”se evaluaronmacroscópicamente.
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Los ojos se recolectaron en los días 1, 2, 3 y 7 después de la cirugía, y se procesaron para
la realización de estudios histológicos.
Resultados: Los valores de pH de las muestras de PRGF aumentaron significativamente
después del proceso de liofilización. Los niveles de osmolaridad aumentaron significa-
tivamente en las muestras de PRGF mezcladas con trehalosa en comparación con las
muestras de PRGF sin protectores. El proceso de liofilización mantuvo los niveles de
factores de crecimiento, así como las propiedades biológicas de los colirios de PRGF,
incluso sin el uso de lioprotectores. El tratamiento con PRGF lyo redujo significativa-
mente el tiempo de reepitelización y la formación de “haze”en las córneas tratadas con
PRK con respecto al grupo de control y PRGF. Además, el grupo PRGF lyo redujo signi-
ficativamente el número de células SMA positivas en comparación con el grupo control
en cada tiempo de estudio y en los días 2 y 3 con respecto al grupo de PRGF.
Conclusiones: el proceso de liofilización conserva el contenido de proteínas y factores
de crecimiento, así como laspropiedadesbiológicas del colirio dePRGF, incluso sin el uso
de protectores. El colirio de PRGF liofilizado acelera la regeneración del tejido corneal
después de la PRK en comparación con el grupo de control.
Relevancia Traslacional: nuestro estudio muestra la viabilidad de preservar la capaci-
dad biológica del colirio de PRGF como formulación liofilizada evitando la adición de
protectores.
Introduction
A wide variety of diseases induce ocular epithelial
and stroma injuries leading to several ocular surface
disorders. The effective healing of these lesions is
essential and necessary to recover the damaged ocular
tissue functionality. The artificial tears are the most
commonly used method for the treatment of ocular
surface diseases. Nevertheless, artificial tears lack most
of the biological features of natural tears, such as
proteins, vitamins, pH, and osmolarity. In addition,
they often contain preservatives, stabilizers, and other
additives that can potentially induce toxic or allergic
reactions.1
An interesting alternative to artificial tears is the use
of blood derivatives. Eye drops obtained from plasma
rich in growth factors (PRGF) represent a poten-
tial therapeutic method for the treatment of ocular
surface pathologies. In addition to their lubricating
properties, eye drops derived from PRGF technology
contain a wide range of proteins that are involved in
ocular regeneration, among which are several growth
factors such as platelet derived growth factor, fibrob-
last growth factor, epidermal growth factor, and trans-
forming growth factor-beta, among others.2,3
This biological method consists of the elabora-
tion of a platelet-enriched plasma obtained from
the patient’s own blood to treat different pathologies
from several medical fields.4–7 After activation, multi-
ple bioactive proteins are released from the platelets,
promoting several biological processes as cell recruit-
ment, proliferation, migration, and cell differentia-
tion.8–10
In recent years, PRGF eye drops have been widely
used in the treatment of several ocular surface diseases,
including dry eye, corneal ulcers, and persistent epithe-
lial defects.11–18 The biochemical and biophysical
properties of PRGF eye drops like pH, osmolarity,
proteins, and growth factors content, which are similar
to the artificial tears, are responsible for the success-
ful results obtained in the treatment of these different
ocular pathologies.19,20
Ocular surface disorders are usually chronic diseases
that require medium- or long-term treatment. There-
fore, the biological functionality and stability of these
treatments need to be maintained for long periods
of time to be used daily for months. In the case of
blood-derived eye drops, several studies have shown
their safety and stability over several months; however,
their long-term storage and throughout the application
period require the use and dependence of a cold chain
(−20°C storage to keep it for a long period of time and
+4°C or room temperature during use).21,22
In contrast, although autologous eye drops are
commonly used for the treatment of ocular disorders,
some patients are not suitable to be donors owing to
systemic inflammatory diseases, age, and other types
of disorders or comorbidities. The possibility of having
available an allogeneic blood-derived product could be
an interesting alternative to treat several ocular surface
diseases in these types of patients.23
In both autologous and allogeneic products, eye
drops lyophilization could be presented as an alterna-
tive to achieve a longer shelf-life for these products,
avoiding a cold chain dependence. The freeze drying
process often modifies protein structures because of
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the low temperature and the higher solute concentra-
tion owing to the freezing procedure.24 Some excipients
such as trehalose are commonly added to the product to
protect the proteins from stress during processing and
storage. The effectiveness of trehalose is related to its
capability to replace some water molecules preventing
uncontrolled dehydration and promoting the protein
stabilization.25
Themain objective of the present studywas to inves-
tigate whether PRGF eye drops preserves their biolog-
ical potential after undergoing a lyophilization process.
The effect of the administration of a lyoprotectant on
the PRGF eye drops before the lyophilization process
was also analyzed. In addition, the regenerative effects
of these preparations onmice cornea after photorefrac-
tive keratectomy (PRK) surgery were evaluated.
Methods
Endoret Preparations
Blood from three healthy donors was collected
after informed consent into 9-mL tubes with
3.8% (wt/v) sodium citrate. The study was performed
following the principles of the Declaration of Helsinki.
Samples were centrifuged at room temperature in
an Endoret System centrifuge (BTI Biotechnology
Institute, S.L., Vitoria, Spain). The whole plasma
column was collected using Endoret ophthalmology
kit (BTI Biotechnology Institute, S.L.) avoiding the
layer containing leukocytes. Platelets and leukocytes
counts were performed with a hematology analyzer
(Micros 60, Horiba ABX, Montpelier, France).
Whole platelet-rich plasma volume was activated with
Endoret activator (BTI Biotechnology Institute, S.L.).
The growth factor enriched supernatants obtained
from each donor was aliquoted in glass vial for
lyophilization and divided in four groups: (1) PRGF:
PRGF supernatant (used as a control), (2) PRGF
lyo: Pure PRGF supernatant frozen at −80°C, (3)
PRGF lyo + 2.5T: PRGF supernatant was mixed with
2,5% trehalose as lyoprotectant and frozen at −80°C;
and finally, (4) PRGF lyof + 5T: PRGF supernatant
was mixed with 5% trehalose and then it was frozen at
−80°C. All samples frozen at −80°C were introduced
in the lyophilizer (LyoBeta, Telstar, Terrassa, Spain)
to carry out the freeze-drying process. The primary
drying phase was carried out at −50°C and 0.1 mBar
for 24 hours. Finally, secondary drying phase was
performed at +20°C and 0.1 mBar for 12 hours. Then,
lyophilized samples were stored at + 4°C until use.
Finally, the different freeze-dried PRGF eye drops
samples were reconstituted with sterilized distilled
water until getting the original volume before be used
in the in vitro and in vivo assays.
Percentage of Water Loss
Percentage of water loss was calculated by weighing
the different PRGF eye drops samples before and after
the freeze-drying process. Dry weight was subtracted
from each sample after their incubation for 24 hours at
60°C. Then, the water loss percent was calculated using
the following equation:
Water loss% = (W0 − Wl)/W0 × 100, (1)
where W0 and Wl is the weight of PRGF eye drops
before and after lyophilization, respectively.
Characterization of PRGF Eye Drops
The concentration of several growth factors
involved in the ocular surface tissue regeneration, such
as epidermal growth factor, platelet-derived growth
factor, transforming growth factor-beta 1, vascular
endothelial growth factor and insulin-like growth
factor type I were analyzed to evaluate the lyophiliza-
tion process effect on the PRGF eye drops. These
growth factors were analyzed using the commercial
enzyme-linked immunosorbent assay kits purchased
from R&D Systems (Minneapolis, MN). The pH
was analyzed with a pH meter (Hach Lange Spain;
Barcelona, Spain), and the osmolarity was measured
with the Advanced Model 3320 Micro-Osmometer
(Tecil, Barcelona, Spain). All of these analyses were
performed on the different PRGF samples obtained
from the three healthy donors.
Cells
The biological activity of eye drops samples
obtained in the present study were evaluated in two
primary cell types from the ocular surface, corneal
keratocytes (called HK) and conjunctival fibroblasts
(termed HConF) (ScienCell Research Laboratories,
San Diego, CA). Both cell types were cultured accord-
ing to manufacturer’s instructions. Briefly, cells were
cultured until confluence in fibroblast medium supple-
mented with fibroblast growth supplement (Complete
FM; ScienCell Research Laboratories) and then were
detached with animal origin-free trypsin like enzyme
(TrypLE Select, Gibco-Invitrogen, Grand Island,
NY). Cell viability was assessed by trypan blue dye
exclusion.
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Proliferation Assay
The ocular surface cells were seeded in a 96-well
dark bottom plate at a density of 10,000 cells/cm2 in
serum-free medium supplemented with 20% (v/v) of
the different PRGF samples obtained from the three
donors. The study period was 72 hours. The cell density
was analyzed using the CYQUANT cell proliferation
assay (Invitrogen, Carlsbad, CA). Briefly, the culture
medium was removed, and the wells were washed
carefully with phosphate-buffered saline. Subsequently,
the plate was frozen at −80°C to produce a better cell
lysis efficiency in the CYQUANT assay. After thawing
the plate at room temperature, the samples were
incubated with RNase A (1.35 Ku/mL) diluted in cell
lysis buffer for 1 hour at room temperature. Then the
2x CyQUANT GR dye/cell lysis solution was added
to each well of the plate, mixed gently and incubated
for 5 minutes at room temperature and protected from
light. The fluorescence of the sample was measured
using a fluorescence microplate reader (Twinkle
LB 970, Berthold Technologies, Bad Wildbad,
Germany). ADNA standard curve ranging from 7.8 to
1000.0 ng/mL was included in all fluorescence
quantifications. Calibration curves ranging from
2500 to 90,000 cells/cm2 were established in each
assay as an index of cell number (CyQUANT assay;
Invitrogen).
Migration Assay
To quantify the migratory potential of the ocular
surface cells after treatment with the different PRGF
eye drops samples obtained in the present study, the
cells were seeded at high density inside the culture
inserts (Ibidi, GmbH, Martinsried, Germany) placed
in a 24-well plate and were grown with fibroblast
growth supplement (Complete FM; ScienCell Research
Laboratories) until confluence. Then the inserts were
carefully removed, and two separated cell monolay-
ers were obtained leaving a cell-free gap of approxi-
mately 500 μm thickness. The cells were washed with
phosphate-buffered saline and incubated in quintupli-
cate with the different eye drops for 24 hours. After
this period, the different culture media were removed,
and the cells were incubated with Hoechst 33342 at
a dilution of 1:500 in phosphate-buffered saline for
10 minutes. To quantify the number of migrated cells,
phase contrast images were taken from the central part
of the gap before treatment and phase contrast and
fluorescence after 24 hours of treatment using a digital
camera coupled to an inverted microscope (Leica
DFC300 FX and Leica DM IRB, Leica Microsystems,
Barcelona, Spain). Image J software (National Insti-
tutes of Health, Bethesda, MD) was used to measure
the gap area taken in each image and the number of
cells migrated after 24 hours.
PRKMouse Model
A total of 120 male C57BL/6 mice were used in
this study. All procedures were performed in accor-
dance with the tenets established in the directive of
the European Parliament and Council of the European
Communities (2010/63/ UE), of the ARVO Statement,
and of the Spanish legislation (RD 1201/2005 and Law
32/2007) for the Use of Animals.
Surgical injury was performed using an Allegretto
WaveLight excimer laser (PR-020407, Wavelight
GmbH, Alcon, Erlangen, Germany) as previously
described.26–30 Right eyes were subjected to PRK
surgery with a 2.0-mm ablation zone on the central
cornea and a depth of 45 μm. The procedure included
the simultaneous ablation of the epithelium (using a
defined epithelial thickness profile of 25 μm centrally)
and 20 μm of the anterior stroma (about 20% of the
total stromal thickness) in a single step. Before the
surgical procedures, mice were deeply anesthetized
by intraperitoneal injection of a mixture of ketamine
hydrochloride (80 mg/kg; Imalgene 1000, Merial
Laboratorios S.A., Barcelona, Spain) and xylazine
hydrochloride (5 mg/kg; Rompun, Bayer Hispania
S.L., Barcelona, Spain) followed by topical applica-
tion of 0.5% tetracaine chlorhydrate and 1 mg of
oxybuprocaine (Colircusí Anestésico Doble, Alcon
S.A., Barcelona, Spain).
Animals were divided in three groups: in the control
group, mice were treated with saline solution (Frese-
nius Kabi, Barcelona, Spain); in the PRGF group, they
were treated with whole fraction of PRGF-Endoret eye
drops; and in the PRGF lyo group, they were treated
with lyophilized whole fraction of PRGF-Endoret and
reconstituted with sterile water at the time of use. In the
in vivo studies, each PRGF formulation (PRGF and
PRGF lyo) from the three donors was pooled before
treating the different eyes to normalize the treatments.
The treatment was administrated topically six times
per day along the first 3 days, and four times per day
until the end of the study. The evolution of the ocular
surface damage in each groupwas analyzed at four time
points: 1, 2, 3, and 7 days of treatment.
Macroscopic Analysis
Corneal wound healing was examined under a
Leica S6D stereoscopic microscope equipped with
an EC3 digital camera (Leica Microsystems) using
a fixed magnification of 12.5×. Observations were
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made immediately after injury and at 1, 2, 3, and 7
days after PRK surgery, and calibrated images were
obtained from each eye. The fluorescein staining test
was used to estimate the area (in square millimeters) of
the corneal epithelial defect using FIJI image analysis
software (ImageJ 1.48d; National Institutes of Health).
Briefly, the region of fluorescein-impregnated cornea
was manually lined with the freehand selection tool
of FIJI on calibrated images. The software automat-
ically calculated the area inside the selection. Previous
to fluorescein staining, the level of opacity in the cornea
(haze grade) was assessed in a double-blinded fashion
by two researchers observing under the stereomicro-
scope, according to the Fantes scale,29 scoring from 0
(clear) to 4 (severely dense opacity).
Tissue Collection and Histopathologic
Analysis
Mice were euthanized under general anesthesia
with an overdose of sodium pentobarbital (Dolethal,
Vétoquinol, Lure, France) injected intraperitoneally
at each time point of the study (1, 2, 3, and
7 days). For histologic analysis, eyes were enucle-
ated and immersed in buffered 4% paraformalde-
hyde and 0.2% picric acid for 1 hour at room
temperature, cryoprotected in 30% sucrose, embed-
ded in OCT compound (Optimum Cutting Temper-
ature; Tissue-Tek, Sakura, Tokyo, Japan), and snap
frozen in liquid nitrogen. Transversal 5-μm-thick
sections were obtained with a Microm HM550
cryostat (Microm International GmbH, Walldorf,
Germany) through the central region of the cornea
for immunofluorescence analysis. Immunofluorescence
assays were performed as described previously using
antibodies to alpha-smooth muscle actin (α-SMA)
(myofibroblast transformation; 1:200; Abcam) and
Ki67 (proliferation marker; 1:500; Abcam).26,27,30,31
Samples were incubated overnight with the corre-
sponding antibody and revealed with an Alexa Fluor
594 anti-rabbit secondary antibody (1:500; Molecu-
lar Probes, Eugene, OR). To detect DNA fragmen-
tation associated with apoptosis, terminal deoxyri-
bonucleotidyl transferase-mediated dUTP-fluorescein
nick-end labeling (TUNEL) was performed on frozen
sections according to the manufacturer’s instructions
(Promega Corp., Madison, WI). Nuclei were counter-
stained with 4’,6-diamidino-2-phenylindole (DAPI;
2 μg/mL; Molecular Probes). Sections were examined
under a Leica DM 6000 fluorescence microscope
equipped with a digital image capture system (Leica
Microsystems).
Quantification of Immunofluorescence and
TUNEL Assay
Three sections (5 μm thick and spaced with
50 μm between them) obtained from the central
region of five corneas for each time point and exper-
imental group were used to quantify Ki-67–positive
proliferative cells, alpha-smooth muscle actin–positive
myofibroblasts, and TUNEL apoptotic cells. Two
independent observers counted every positive cell
with clearly identifiable nuclei stained in blue with
DAPI on five non-overlapping corneal regions of
224.14 × 167.38 μm in size. Each microscope field
comprised a column of central corneal tissue extending
from the anterior epithelium to the posterior stromal
surface.
Statistical Analysis
A general linear model repeated-measures analysis
of variance was used to analyze the differences among
the PRGF eye drops obtained in the present study for
the different variables studied. The significance of the
post hoc comparisons was calculated with the Bonfer-
roni correction. In the case of an in vivo assay, the
nonparametric Kruskal-Wallis test with a subsequent
Mann-Whitney analysis test for multiple comparisons
between groups were used. A difference at a level of a
P of less than 0.05 was considered to be statistically
significant. Statistical analyses were performed using
SPSS software (version 15.0; SPSS Inc., Chicago, IL).
Results
The mean platelet enrichment of the Endoret
preparations was 2.14-fold over the baseline concen-
tration of platelets in whole blood. The PRGF
platelet concentration obtained from the three donors
ranged from 284 to 434 × 103 platelets/μL. None
of the preparations contained detectable levels of
leucocytes.
Freeze-Drying of PRGF Eye Drops
After PRGF eye drops lyophilization a kind of
homogeneous soft wafer (Fig. 1A) was obtained that
it can be easily broken getting a yellowish powder. The
wafers obtained from the three groups of lyophilized
PRGF eye drops (Fig. 1B: PRGF lyo, PRGF lyo+2.5T,
and PRGF lyo+5T) had similarmorphologic and color
features (Fig. 1C). The different lyophilized PRGF eye
drops samples were rehydrated in an equal volume
of distilled water to return them to their original
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Figure1. Representative imagesof thePRGFeyedrops appearancealong the freeze-driedprocedure. (A)Akindof yellowishhomogeneous
waferwasobtainedafter PRGF lyophilization.Different PRGFeyedrops samples analyzedalong the study (PRGF lyo, PRGF lyo+2.5T, andPRGF
lyo+5T) before their lyophilization (B), after the freeze-dried process (C), and after their reconstitution with equal bulk of distilled water to
the original volume (D).
concentration. The reconstitution of each sample was
almost instantaneous obtaining a homogeneous and
cloudy solution in all samples used in the present study
(Fig. 1D).
Percentage of Water Loss
No significant differences (P > 0.05) were observed
in the percentage of water loss among the different
freeze-dried PRGF eye drops samples obtained along
the study. As it is shown in Figure 2, the percentage of
water loss in freeze-dried PRGF eye drops (PRGF lyo)
reached a 97.19%, similar to the water loss obtained in
those PRGF eye drops mixed with trehalose at 2.5% or
5% achieving also a 97.18% and 97.22% of water loss,
respectively.
Characterization of PRGF Eye Drops
The concentration of several growth factors
involved in ocular surface regeneration were analyzed
in the PRGF eye drops stored at −20°C (PRGF),
freeze-dried PRGF without lyoprotectants (PRGF lyo)
and mixed with 2.5% trehalose (PRGF lyo+2.5T) or
5% (PRGF lyo+5T). The levels of the different growth
factors analyzed are presented in Table 1. The results
shown that the concentration of the different growth
factors analyzed were kept constant after lyophiliza-
Figure 2. Percentage of water loss after the lyophilization process
of the different PRGF eye drops samples obtained in the study.
tion of the PRGF eye drops with or without lyopro-
tectant with respect to the control group (Table 1).
The measurement of pH in the different PRGF eye
drops samples showed that lyophilization process
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Table 1. Concentrations of Several Growth Factors in the Different PRGF Eye Drops
PDGF-AB (pg/mL) TGF-β1 (ng/mL) VEGF (pg/mL) EGF(pg/mL) IGF(ng/mL)
PRGF (n = 3) 17,300 ± 3204 23,963 ± 1879 196 ± 92 556 ± 18 90 ± 3
PRGF lyo (n = 3) 15,485 ± 5413 20,950 ± 841 174 ± 135 493 ± 86 84 ± 4
PRGF lyo+2.5T (n = 3) 15,683 ± 4902 22,138 ± 4038 164 ± 81 509 ± 2 83 ± 1
PRGF lyo+5T (n = 3) 14,133 ± 3220 20,463 ± 4946 171 ± 53 555 ± 59 80 ± 10
EGF, epidermal growth factor; IGF, insulin-like growth factor; PDGF, platelet-derived growth factor; TGB-β1, transforming
growth factor-beta1; VEGF, vascular endothelial growth factor.
Data represent mean ± standard deviation. No significant differences (P > 0.05) were observed in the levels of the growth
factors analyzed among the different samples of PRGF eye drops.
Table 2. pH and Osmolarity Values (mean ± SD) Measured in Each PRGF Eye Drop Samples
PRGF PRGF+2.5T PRGF+5T PRGF lyo PRGF lyo+2.5T PRGF lyo+5T
pH 7.53 ± 0.09a,b,c 7.59 ± 0.08a,b,c 7.58 ± 0.09a,b,c 8.54 ± 0.13*,† ,‡,b,c 8.32 ± 0.18*,† ,‡,a,c 8.20 ± 0.18*,† ,‡,a,b
Osmolarity (mOsm/Kg) 319 ± 7† ,‡,b,c 394 ± 7*,‡,a 488 ± 19*,† ,a,b,c 301 ± 6† ,‡,b,c 376 ± 6*,‡,a,c 440 ± 18*,‡,a,b
Data representmean± standard deviation. *Statistically significant regarding PRGF (P< 0.05). †Statistically significant respecting PRGF+2.5T (P< 0.05). ‡Statistically significant
regarding PRGF+5T (P< 0.05). aStatistically significant with respect to PRGF lyo (P< 0.05). bSignificant differences with respect to PRGF lyo+2.5T (P< 0.05). cStatistically significant
with respect to PRGF lyo+5T (P < 0.05).
increased the pH levels becoming statistically signifi-
cant (P < 0.05) in comparison to fresh PRGF samples
(PRGF, PRGF+2.5T and PRGF+5T) (Table 2).
No significant differences were observed among the
fresh PRGF eye drops samples mixed or not with
trehalose. However, significant differences (P < 0.05)
were observed among the different freeze-dried PRGF
eye drops samples, reaching the highest pH values in
the freeze-dried PRGF eye drops samples (PRGF lyo)
(pH of 8.54), followed by PRGF+2.5T samples (pH
of 8.32) and PRGF lyo+5T samples (pH of 8.20).
Osmolarity values increased significantly (P < 0.05)
in PRGF samples mixed with trehalose in compar-
ison to PRGF without lyoprotectans (PRGF and
PRGF lyo) (Table 2). This osmolarity level increase
was correlated with the trehalose percentage applied
to PRGF eye drops. Osmolarity values increased in
fresh samples from 319 in PRGF to 394 and 488 in
PRGF+2.5T and PRGF+5T, respectively, whereas
in the freeze-dried samples the levels increased from
- 301 in PRGF lyo group to 376 in PRGF lyo+2.5T and
440 in PRGF lyo+5T. However, the results showed that
the lyophilization process maintained the osmolarity
values between the fresh PRGF samples and their
corresponding freeze-dried samples.
Biological Activity of Freeze-Dried PRGF Eye
Drops
The biological activity was measured as prolifera-
tive and migratory potential of freeze-dried PRGF eye
drops samples in HK and HConF cells. Both types of
cells showed no significant differences in proliferation
and migration levels after treatment with the differ-
ent PRGF eye drops samples obtained along the study
(Fig. 3).
Macroscopic Analysis
No adverse reactions were found on mice ocular
surface tissues after treatment with human recon-
stituted freeze-dried PRGF eye drops. Partial re-
epithelization was observed in all mice eyes at the first
time point (day 1) showing no differences among the
treatment groups (Fig. 4A). On the second day, the
fluorescein positive corneal lesion areawas significantly
decreased in the PRGF lyo–treated eyes compared
with PRGF and control eyes (P < 0.01) (Fig. 4B).
Furthermore, 55% of the eyes treated with PRGF lyo
presented a total re-epithelization, whereas only 20%
of control eyes showed successfully closed epithelium
at day 2. However, none of the mouse corneas treated
with PRGF were completely closed at day 2 of treat-
ment. All eyes in PRGF lyo group were completely
re-epithelized at day 3, whereas 40% of the control
group and a 45% of the PRGF group corneas remained
damaged. Moreover, 20% of the eyes in the group
treated with saline showed small focus of fluorescein
stained defects at the end of the study (day 7) (Fig. 4A).
In the case of the PRGF group, all corneas were
completely re-epithelized at day 7.
At the same time, PRK-treated corneas were
analyzed in the different treatment groups to evaluate
the haze development at each time point (Fig. 5A). The
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Figure 3. Biological activity of corneal keratocytes (HK) and conjunctival fibroblasts (HConF) after culture with PRGF eye drops (PRGF; n=
3) or freeze-dried PRGFwithout lyoprotectans (PRGF lyo; n= 3) or mixed with 2.5% (n= 3) or 5% (n= 3) trehalose (PRGF lyo+2.5T and PRGF
lyo+5T, respectively). No significant differences were observed in the proliferation index, nor in the migration activity of the HK and HConF
cells after being cultured with the different study samples.
mouse corneas treated with PRGF lyo showed lower
grade of stromal haze than control group from day
2 to the end of the study. Thus, corneas treated with
PRGF lyo were significantly (P < 0.05) more transpar-
ent than in saline group at days 2, 3, and 7 after PRK
(Fig. 5B). Moreover, haze formation was significantly
reduced after PRGF lyo treatment in the PRGF group
at day 3 of the study. In contrast, PRGF treatment
decreased significantly haze formation in comparison
to the control group at day 7 of treatment (Fig. 5B).
Histologic Analysis
Proliferation
Ki-67–positive cells increased drastically in all mice
corneal epithelium near to limbal area at day 1 after
PRK surgery, showing a wave of Ki-67–positive cells
from the periphery to the center of the cornea. At
this point, the center of the cornea was not covered
by epithelium, but some Ki-67–positive cells seemed
to organize in rows at the surface of the injured area
(Fig. 6). At day 1 of treatment, statistically signifi-
cant differences (P < 0.05) were only found between
PRGF-treated and control corneas in the number of
epithelial Ki-67–positive cells, whereas no differences
were found between the corneas treated with PRGF
lyo and control group at this time in the study. The
greatest epithelial proliferation rate was observed at
day 2 after injury, decreasing progressively the number
of Ki-67–positive cells until the end of the study.
PRGF lyo and PRGF corneas exhibited a significantly
(P < 0.05) lower number of proliferative cells at 2,
3, and 7 days after surgery compared with control
corneas. Seven days after injury, the number of Ki-67–
positive cells in the mice corneas treated with PRGF
(71.4 ± 4.86 cells) and with PRGF lyo (71.62 ± 2.49
cells) was near the normal number of proliferative cells
in an uninjured cornea (58.66± 4.41 cells), whereas the
number of proliferative cells in saline group was three
times higher (144.50 ± 3.83 cells).
Apoptosis
TUNEL-positive cells were detected in high number
at day 1 after surgery in mice corneal stroma (Fig. 7).
The number of apoptotic cells decreased progres-
sively until basal levels at day 7. At this moment,
TUNEL-positive cells were only detected at the super-
ficial epithelial layer of flat cells. No statistical differ-
ences were detected among the treatment groups in
the number of apoptotic cells excepting for 3-day
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Figure 4. Macroscopic analysis of corneal wound healing stained with fluorescein after PRK surgery. (A) Representative images of corneal
wound healing at different time points of the study of the different treatment groups. At the end of the study (day 7) slightly corneal fluores-
cence staining were observed in some mice of the control group. (B) Significant differences in the area of corneal wound healing were
observed in mice treated with PRGF lyo at 2 and 3 days after surgery in comparison with the control and PRGF groups. At day 3, all of the
mice corneas treated with PRGF lyo were completely closured, whereas in the control group at least 20% of the corneas remained unclosed
at the end of the study (day 7). Results have been expressed as amean area of wound healing± standard error of themean (n= 10 per treat-
ment group). *Statistically significant differences between the PRGF lyo and control groups (P < 0.05). #Statistically significant differences
between PRGF lyo and PRGF group (P < 0.05).
time point, where PRGF lyo–treated eyes showed a
significant reduced number of TUNEL-positive cells
compared with control treated eyes (P < 0.05).
Immunofluorescence Detection of Myofibroblasts
The first α-SMA positive cells identified as myofi-
broblasts were observed at day 2 after injury, being the
amount of α-SMA–positive cells significantly higher
(P < 0.001) in the control group (9.20 ± 0.63 cells) and
in the PRGF group (7.60± 0.67) compared with scarce
cells observed in PRGF lyo group (0.88 ± 0.35 cells)
(Fig. 8). Only 44% of the eyes in the group treated with
PRGF lyo presented α-SMA immunoreactivity in the
stroma while 100% of the control and PRGF groups
showed α-SMA–positive cells.
At day 3 the number of myofibroblasts in the
control group increased (11.73 ± 0.83 cells). However,
the number of α-SMA–positive cells was decreased in
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Figure 5. Macroscopic analysis of haze development after PRK surgery. (A) Representative images of mice corneas from the different treat-
ment groups at different times of the study. PRGF lyo and PRGF treatments decreased corneal haze formation showing transparent corneas
at days 3 and 7 after PRK surgery, respectively. However, corneal haze was observed along the study in mice corneas of the control group.
(B) Haze development was significantly decreased in corneas treated with PRGF lyo eye drops regarding those treated with control from
day 2 to the end time of the study. In addition, corneas treated with PRGF lyo showed a significant reduction in the corneal haze formation
in comparison to PRGF group at day 3 of treatment. In contrast, haze formation was significantly reduced after PRGF treatment regarding
control group at day 7 of the study. Results have been expressed as a mean haze grade± standard error of the mean (n= 10 per treatment
group). *Statistically significant differences between the PRGF lyo and control groups (P< 0.05). #Statistically significant differences between
PRGF lyo and PRGF group (P < 0.05). ‡Statistically significant differences between PRGF and control group (P < 0.05).
PRGF and PRGF lyo-treated corneas, showing a lack
of α-SMA staining cells in the mice corneas treated
with PRGF lyo at this time point. Significant differ-
ences were observed in the number of SMA positive
cells in the corneas treated with PRGF and PRGF
lyo regarding the control group at day 3. In addition,
PRGF lyo decreased significantly the number of cells
stainedwith SMA in comparisonwith the PRGFgroup
at this time of the study.
Seven days after surgery, there was a significant
decrease (P < 0.05) in the quantity of α-SMA–positive
myofibroblasts in PRGF lyo (4.33 ± 0.83 cells) and
Downloaded from tvst.arvojournals.org on 05/11/2021
Development of Freeze-Dried PRGF Eye Drops TVST | June 2020 | Vol. 9 | No. 7 | Article 35 | 11
Figure 6. Histologic analysis of Ki-67–positive cells after PRK surgery. Representative images of the central area of the cornea of uninjured
cornea and the different treatment groups at each time point of the study showing Ki-67–positive cells stained in red and cell nuclei in blue.
Control treatment increased significantly the number of Ki-67–positive cells (mean± standard error of themean) inmice corneal epithelium
at each time of the study regarding PRGF group and at 2, 3, and 7 days from surgery in comparison to the PRGF lyo treatment. n = 10 per
treatment group and per study time. *Statistically significant differences in comparison to PRGF lyo group (P< 0.05). ‡Statistically significant
differences with respect to PRGF group (P < 0.05). Scale bar: 50 μm.
PRGF (6.00 ± 0.38) treatment groups compared with
control (13.25 ± 1.16 cells; P < 0.001). Myofibroblasts
were located at the uppermost layers of the anterior
stroma, forming a thick layer in contact with the basal
epithelial cells in the control group (Fig. 8). Most of
the myofibroblasts were observed in zones where the
inferior epithelial border was not regular or presented
a non-mature aspect. Corneas from PRGF and PRGF
lyo groups showed a restored multilayered epithelium
with an organized and linear basal cell layer and
presented a low amount of myofibroblasts.
Discussion
The tear film is composed of a wide content in
electrolytes, mucins, proteins, and peptides that confer
it particular characteristics such as lubrication, biolog-
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Figure 7. Histologic analysis of apoptotic cells using TUNEL immunofluorescence technique after PRK surgery. Representative images of
the central area of the cornea of uninjured cornea and the different treatment groups at each time point of the study. A high number of
TUNEL-positive cells stained in greenwere detected at day 1 after surgery inmice corneal stroma, cell nuclei are stained in blue. The number
of TUNEL+ cells (mean ± standard error of the mean) were progressively decreasing until reaching similar levels of untreated corneas at
day 7 from surgery. n= 10 per treatment group and per study time. Significant differences (*,P< 0.05) were observed between control and
PRGF lyo treatment groups at day 3 after PRK surgery. Scale bar: 50 μm.
ical activity and antimicrobial effect.32 In the last years,
the development of a product similar to the natural tear
has reached a great interest to be used in the treatment
of the ocular surface diseases. The use of blood deriva-
tive products is not new and their beneficial effects in
the ophthalmology field is attributed to their proper-
ties and protein content similar to the natural tears.
It contains a wide range of functional proteins such
as growth factors and vitamins, that regulate prolifer-
ation, migration, and differentiation processes of the
ocular surface cells.33
In recent decades, several studies have demonstrated
the effectiveness and safety of the autologous blood-
derived eye drops as an alternative treatment for several
ocular surface disorders.12,18,34,35 However, autologous
blood donation is not suitable for some patients owing
to systemic inflammatory diseases, age, and other
types of disorders or comorbidities. An allogeneic
blood-derived product could be an alternative for
these patients to treat several ocular surface diseases.23
Furthermore, in some countries like theUK,Germany,
and New Zealand the production of blood-derived eye
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Figure 8. Representative images of α-SMA immunofluorescence of the different treatment groups at 7 days after PRK surgery. A higher
number of SMA-positive cells were observed in control mice corneas regarding PRGF lyo and PRGF. At this time of treatment, SMA-positive
cells were just detected underneath corneal epithelium. PRGF lyo decreased significantly (P < 0.05) the number of SMA positive cells in
comparison to control group at 2, 3 and 7 days after PRK surgery and regarding PRGF treatment at day 2 and 3. SMA-positive cells were
significantly decreased after treatment with PRGF in comparisonwith the controls at days 3 and 7 after PRK surgery. Results are expressed as
themeannumber of SMA-positive cells± standard error of themean.n=10per treatment groupandper study time. *Statistically significant
differences between PRGF lyo and control group (P< 0.05). #Statistically significant differences between PRGF lyo andPRGFgroup (P< 0.05).
‡Statistically significant differences between PRGF and control group (P < 0.05). Scale bar: 50 μm.
drops is regulated by different regulatory agencies, and
its manufacturing is centralized in hospitals or blood
banks.36 This situation causes some concerns to the
patients as the need to travel from the specialist’s office
to the nearest hospital and to wait during hours in the
hospital until the drops are ready.36 In fact, some blood
derivatives manufacturing take 2 to 3 days and also
in some countries like Germany competent authorities
might require to quarantine eyedrop preparations for
bacterial contamination testing, which could take up to
1 to 2 weeks.37 Therefore, allogeneic blood derived eye
drops could be an alternative for supplying hospitals to
solve the problems derived from the use and manufac-
ture of autologous products. A high quantity of “off-
the-shelf” allogeneic blood derived eye drops can be
produced, improving the logistics of the treatment.38
In recent years, theNewZealandBlood Service Clinical
Advisory Group and the regulatory authority in New
Zealand (Medsafe) has approved the use of allogeneic
blood derived eye dropswhen the use of autologous eye
drops was not feasible or clinically possible.39
The freeze-drying process could be an alternative to
increase the shelf-life of this blood derived product and
to facilitate the accessibility in an off-the-shelf manner.
In the present work, we have observed that water
content after PRGF eye drops lyophilization was less
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than 5% considering this percentage as an adequate in
a freeze-dried process.40 Then, the different lyophilized
PRGF eye drops samples were reconstituted with a
bulk of distilled water equal to their original volume.
The chemical analyses of the different samples showed
that pH values increased significantly after lyophiliza-
tion until reaching their highest values to 8.54 in the
case of PRGF lyo. However, preclinical and clinical
studies have demonstrated that eye drops formulations
should have a pH between 6.6 and 9.0 to avoid irrita-
tion.41 Our results show that pH in all of the PRGF
samples analyzed remained under 9.0 value indicat-
ing that they are perfectly tolerated by the ocular
tissues.
The normal tear has an osmolarity levels ranged
between 300 and 310 mOsm/kg.42 Various clinical
studies have demonstrated that osmolarity levels higher
than 425 mOsm/kg induce an inflammatory response
on ocular surface cells triggering a discomfort feeling
in patients with dry eyes.43 Our results show that
pure PRGF eye drops samples maintain the osmolar-
ity values in similar levels to those of the normal tears
even after the lyophilization process. However, PRGF
eye drops samples mixed with trehalose could exert an
adverse effect on ocular surface tissues in patients with
dry eye owing the higher osmolarity levels achieved
after the addition of protectants.43,44
In recent years, several studies have shown that
lyophilization of different blood-derived products
mixed with lyoprotectants like trehalose maintain their
biological properties.45 However, in this study, we have
demonstrated that PRGF eye drops can be lyophilized
without the use of lyoprotectants maintaining all of
their chemical and biological properties.
Similar results were observed in the in vivo model
where PRGF lyo demonstrated faster wound healing
than PRGF and control groups. The cause of the
higher re-epithelialization capability of PRGF lyo in
contrast with the PRGF could be due to the higher
migratory activity of PRGF lyo after its storage for
a few months at 4°C or at room temperature.46 In
this sense, some proteins or growth factors involved
in the control/inhibition of cell migration could be
partially or totally denaturalized during freeze-drying
process or during the storage period reducing the re-
epithelialization time of mice corneas treated with
PRGF lyo. However, further studies will be needed to
evaluate the proteins and growth factors involved at
this study point. However, the re-epithelization capac-
ity of the treatment groups observed in in vivo models
was not correlated with the number of proliferative
cells (ki-67–positive) at each time of treatment. The
faster re-epithelization of PRGF lyo is probably due to
the higher migratory capability of PRGF eye drops in
comparison to the control treatment as it was observed
in a previous study.27 Furthermore, this increase in the
epithelial cell proliferation of the control group could
be related with the irregular epithelia observed at the
end of the study in contrast to the mice corneal epithe-
lium treated with PRGF and PRGF lyo, where it was
closely similar to the native corneal epithelium.
In addition, the higher corneal haze observed in
the control and PRGF groups in comparison with the
PRGF lyo–treated mice from the second to seventh
day of treatment were correlated with the detection of
SMA+ cells in the different treatment groups. PRGF
lyo eye drops decreased significantly (P < 0.05) the
number of SMA-positive cells on stromal corneas
regarding the control group at 2, 3, and 7 days of treat-
ment, whereas this significant decrease was observed
between the PRGF lyo group and the PRGF group at
days 2 and 3 of treatment. The presence of myofibrob-
last cells (SMA-positive cells) is highly related with the
development of corneal haze, which is correlated with
the results observed by biomicroscopic analysis in the
different groups at each time of the study.
A TUNEL assay showed no differences among
groups of treatment, except at day 3, where a significant
decrease in the number of apoptotic cells were observed
in the corneas treated with PRGF lyo in comparison
with the control group. This difference was due to the
no changes observed in the number of apoptotic cells
between days 2 and 3 after surgery in the control group
in contrast with the PRGF group, where the number of
apoptotic cells were progressively decreasing along the
study time.
Although further investigation is needed, the
present results suggest that the lyophilization process
could increase the shelf-life of the PRGF eye drops
and could improve the shipping and storage procedure
in comparison with the actual storage temperature
restrictions.21,46
Conclusions
The results obtained in the present study show that
freeze-dried PRGF eye drops maintain their protein
and growth factors content as well as their biologi-
cal properties, even without the use of lyoprotectants.
The therapeutic effects of lyophilized PRGF eye drops
may be comparable to those of fresh PRGF eye drops
in the treatment of ocular surface disorders. Freeze-
dried PRGF eye drops could be an alternative as
an off-the-shelf product to be used as an allogeneic
eye drops for the treatment of several ocular surface
diseases.
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